Glial cell line-derived neurotrophic factor
( DrugBank: - / KEGG DRUG: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 6 | パーキンソン病 | 6 |
6. パーキンソン病
臨床試験数 : 2,307 / 薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199
Showing 1 to 6 of 6 trials
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04167540 (ClinicalTrials.gov) | April 1, 202020200401 | 7/11/201920191107 | GDNF Gene Therapy for Parkinson's Disease | Open-Label Safety Study of Glial Cell Line-Derived Neurotrophic Factor Gene Transfer (AAV2- GDNF) in Parkinson's Disease Open-Label Safety Study of Glial Cell Line-Derived Neurotrophic FactorGene Transfer (AAV2- GDNF) in ... | Parkinson's Disease | Biological: AAV2-GDNF | Brain Neurotherapy Bio, Inc. | Asklepios Biopharmaceutical, Inc.;California Institute for Regenerative Medicine (CIRM) | Active, not recruiting | 35 Years | 75 Years | All | 11 | Phase 1 | United States |
| 2 | EUCTR2013-001881-40-GB (EUCTR) | 16/09/201320130916 | 05/08/201320130805 | Extension study to Assess the Benefit and Safety of Administering Intermittent GDNF Infusions in Parkinson's Disease (PD) Extension study to Assess the Benefit and Safety of Administering Intermittent GDNF Infusions in Par ... | An Extension Study to Assess the Safety and Efficacy of Intermittent Bilateral Intraputamenal Glial Cell Line-Derived Neurotrophic Factor (GDNF) Infusions Administered via onvection Enhanced Delivery (CED) in Subjects with Parkinson’s Disease - Intermittent Bilateral GDNF for Parkinson’s Disease An Extension Study to Assess the Safety and Efficacy of Intermittent Bilateral Intraputamenal Glial ... | Parkinson's disease MedDRA version: 18.1;Level: LLT;Classification code 10034008;Term: Parkinson's syndrome;System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] Parkinson's disease MedDRA version: 18.1;Level: LLT;Classification code 10034008;Term: Parkinson's s ... | Product Name: Glial Cell Line-Derived Neurotrophic Factor (GDNF) INN or Proposed INN: Liatermin Other descriptive name: r-metHuGDNF Product Name: Glial Cell Line-Derived Neurotrophic Factor(GDNF) INN or Proposed INN: Liatermin Other d ... | North Bristol NHS Trust (NBT) | NULL | Not Recruiting | Female: yes Male: yes | 42 | Phase 2 | United Kingdom | ||
| 3 | NCT01621581 (ClinicalTrials.gov) | March 13, 201320130313 | 14/6/201220120614 | AAV2-GDNF for Advanced Parkinson s Disease | A Phase 1 Open-Label Dose Escalation Safety Study of Convection Enhanced Delivery (CED) of Adeno-Associated Virus Encoding Glial Cell Line-Derived Neurotrophic Factor (AAV2-GDNF) in Subjects With Advanced Parkinson's Disease. A Phase 1 Open-Label Dose Escalation Safety Study of Convection Enhanced Delivery (CED) of Adeno-Ass ... | Parkinson's Disease | Genetic: Convection enhanced delivery/AAV2-GDNF | National Institute of Neurological Disorders and Stroke (NINDS) | NULL | Completed | 18 Years | N/A | All | 25 | Phase 1 | United States |
| 4 | NCT03652363 (ClinicalTrials.gov) | October 25, 201220121025 | 21/8/201820180821 | GDNF in ideopathicParkinsons Disease | A Placebo-Controlled, Randomised, Double-Blind Trial to Assess the Safety and Efficacy of Intermittent Bilateral Intraputamenal (GDNF) Infusions Administered Via Convection Enhanced Delivery (CED) in Subjects With Parkinson&Apos;s Disease A Placebo-Controlled, Randomised, Double-Blind Trial to Assess the Safety and Efficacy of Intermitte ... | Idiopathic Parkinson Disease | Drug: glial cell line-derived neurotrophic factor | North Bristol NHS Trust | NULL | Completed | 35 Years | 75 Years | All | 42 | Phase 2 | NULL |
| 5 | EUCTR2011-003866-34-GB (EUCTR) | 24/09/201220120924 | 01/05/201220120501 | Assessing the Benefit and Safety of Administering Intermittent GDNF Infusions in Parkinson's Disease (PD) Assessing the Benefit and Safety of Administering Intermittent GDNF Infusions in Parkinson's Disease ... | A Placebo-Controlled, Randomised, Double-Blind Trial to Assess the Safety and Efficacy of Intermittent Bilateral Intraputamenal Glial Cell Line-Derived Neurotrophic Factor (GDNF) Infusions Administered via Convection Enhanced Delivery (CED) in Subjects with Parkinson’s Disease - Intermittent Bilateral GDNF for Parkinson’s Disease A Placebo-Controlled, Randomised, Double-Blind Trial to Assess the Safety and Efficacy of Intermitte ... | Parkinson's disease MedDRA version: 18.1;Level: LLT;Classification code 10034008;Term: Parkinson's syndrome;System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] Parkinson's disease MedDRA version: 18.1;Level: LLT;Classification code 10034008;Term: Parkinson's s ... | Product Name: Glial Cell Line-Derived Neurotrophic Factor (GDNF) INN or Proposed INN: Liatermin Other descriptive name: r-metHuGDNF Product Name: Glial Cell Line-Derived Neurotrophic Factor(GDNF) INN or Proposed INN: Liatermin Other d ... | North Bristol NHS Trust (NBT) | NULL | Not Recruiting | Female: yes Male: yes | 42 | Phase 2 | United Kingdom | ||
| 6 | NCT00006488 (ClinicalTrials.gov) | October 200020001000 | 8/11/200020001108 | Continuously Infused Intracerebral (IC) Recombinant-Methionyl Human Glial Cell Line-Derived Neurotrophic Factor (r-metHuGDNF) for the Treatment of Idiopathic Parkinson's Disease Continuously Infused Intracerebral (IC) Recombinant-Methionyl Human Glial Cell Line-Derived Neurotro ... | Parkinson Disease | Drug: recombinant-methionyl human glial cell line-derived neurotrophic factor | National Center for Research Resources (NCRR) | NULL | Completed | 18 Years | 75 Years | Both | Phase 1 | United States |